Volker Heinemann

Has grant

Professor, M.D

Ludwig-Maximilians-Universität München
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Post-resection therapy in patients with metastatic colorectal Cancer (PORT) AIO KRK01418

Open Date: 2021-01-01

Close Date:

Articles (12)

Forest plot of univariate Cox Regression Analysis of progression-free survival and overall survival within epithelial tumor expression in the invasive margin and overall stromal expression of the induction therapy set.

Year:

2025

Purpose: Tumor immune cell infiltration patterns in the tumor microenvironment serve as prognostic biomarkers in metastatic colorectal cancer. This study analyzed the spatially resolved tumor immune microenvironment for prognostic and predictive impact in patients with RAS wild-type metastatic colorectal cancer receiving 5-fluoruracil/folinic acid ± panitumumab (Pmab) maintenance after Pmab + fluorouracil, folinic acid, and oxaliplatin induction (PanaMa AIO KRK0212; NCT01991873). Patients and Methods: Twelve immune parameters (lymphocyte markers: CD3, CD8, CD45RO, FOXP3, CD20, granzyme B, and perforin; immune checkpoints: PD-1, PD-L1, IDO1, and LAG3; and monocyte marker CD163) were quantified in spatially resolved tumor and stroma regions [invasive-margin (Inv) and center (Cen)] on tissue microarrays from available surgical resections using digital pathology. Prognostic and predictive associations were assessed using percentile cutoffs, immunoscore (IS), PD-L1 combined positive score, and an immunoactivation score (IAS). The median progression-free (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method, log rank test, and Cox regression. Results: In 194 patients, low CD163 and high PD-1 in the tumor center were independent prognostic factors for prolonged PFS, whereas high central LAG3 was associated with improved OS. Pmab maintenance conferred PFS benefit in patients with low CD3 InvStr , CD8 Inv , LAG3 CenTum , CD163 CenTum , and IS and high CD45RO Cen . CD45RO Cen high and LAG3 Cen low also predicted OS benefit. A positive IAS (≥2 predictive markers) identified patients deriving significant PFS (HR = 0.50; 95% confidence interval, 0.32–0.76; P P = 0.009) benefit from Pmab. Conclusions: Immune microenvironment factors, including CD3, CD8, CD163, LAG3, CD45RO, IS, and IAS, predict benefit from Pmab maintenance, suggesting immune activation as a key component of anti-EGFR efficacy.

Year:

2025

P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Induction Set

Year:

2025

P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Maintenance Set.

Year:

2025

Purpose: Tumor immune cell infiltration patterns in the tumor microenvironment serve as prognostic biomarkers in metastatic colorectal cancer. This study analyzed the spatially resolved tumor immune microenvironment for prognostic and predictive impact in patients with RAS wild-type metastatic colorectal cancer receiving 5-fluoruracil/folinic acid ± panitumumab (Pmab) maintenance after Pmab + fluorouracil, folinic acid, and oxaliplatin induction (PanaMa AIO KRK0212; NCT01991873). Patients and Methods: Twelve immune parameters (lymphocyte markers: CD3, CD8, CD45RO, FOXP3, CD20, granzyme B, and perforin; immune checkpoints: PD-1, PD-L1, IDO1, and LAG3; and monocyte marker CD163) were quantified in spatially resolved tumor and stroma regions [invasive-margin (Inv) and center (Cen)] on tissue microarrays from available surgical resections using digital pathology. Prognostic and predictive associations were assessed using percentile cutoffs, immunoscore (IS), PD-L1 combined positive score, and an immunoactivation score (IAS). The median progression-free (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method, log rank test, and Cox regression. Results: In 194 patients, low CD163 and high PD-1 in the tumor center were independent prognostic factors for prolonged PFS, whereas high central LAG3 was associated with improved OS. Pmab maintenance conferred PFS benefit in patients with low CD3InvStr, CD8Inv, LAG3CenTum, CD163CenTum, and IS and high CD45ROCen. CD45ROCen high and LAG3Cen low also predicted OS benefit. A positive IAS (≥2 predictive markers) identified patients deriving significant PFS (HR = 0.50; 95% confidence interval, 0.32–0.76; P < 0.001) and OS (HR = 0.54; 95% confidence interval, 0.33–0.86; P = 0.009) benefit from Pmab. Conclusions: Immune microenvironment factors, including CD3, CD8, CD163, LAG3, CD45RO, IS, and IAS, predict benefit from Pmab maintenance, suggesting immune activation as a key component of anti-EGFR efficacy.

Year:

2025

Supplementary Data Figure 1. PDX show high correlation within the same patient line across different runs compared to different patient lines on the same run. Supplementary Data Figure 2. Mouse kinase expression is not line specific and does not associate with tumor molecular subtype. Supplementary Data Figure 3. Molecular subtyping in PDX model recapitulates basal-like and classical tumor specific subtypes. Supplementary Data Figure 4. Subtype specific kinase expression is associated with gene expression in PDX tumors. Supplementary Data Figure 5. Kinase expression from patients reflects the PDAC PDX kinome. Supplementary Data Figure 6. Overall survival (OS) and treatment response of patients who received EGFR inhibitors.

Year:

2025

Effective therapies for pancreatic ductal adenocarcinoma (PDAC) have been largely elusive. In this study, we perform multiplexed kinase inhibitor bead mass spectrometry on 102 patient-derived xenografts derived from 14 unique primary PDACs to define the tumor-intrinsic kinome landscape. Our findings uncover three kinome subgroups making up two tumor-intrinsic kinome subtypes that we call kinotypes. The kinotypes show enrichment of different kinase classes and recapitulate previously described molecular subtypes, basal-like and classical. The kinotype characterizing basal-like tumors shows enrichment of receptor tyrosine kinases, whereas the kinotype characterizing classical tumors is enriched in understudied kinases involved in Wnt signaling and immune pathways. We validate our findings in two clinical trials and show that only patients with basal-like tumors derive significant benefit from EGFR inhibitors. Our results provide a comprehensive tumor-intrinsic kinome landscape of PDAC that strongly supports actionable kinotype-specific kinase targets and provides a roadmap for kinase inhibitor therapy in PDAC. Significance: We provide a comprehensive tumor-intrinsic kinome landscape that provides a roadmap for the use of kinase inhibitors in PDAC treatment approaches.

Year:

2025

BACKGROUND Transcriptional subtypes of pancreatic ductal adenocarcinoma (PDAC) have prognostic implications and potential predictive functions. This study aimed to determine their clinicopathological impact in large cohorts of advanced and resected PDAC and their evolution during disease progression. METHODS The clinicopathological and prognostic implications of transcriptional subtypes determined by the expression of KRT81, HNF1A and GATA6 were examined using immunohistochemistry in advanced (n=139) and resected (n=411) PDAC samples as well as in 57 matched primary tumors and corresponding metastases. RNAseq data of 316 resected PDAC patients was analyzed for validation. RESULTS Both subtyping systems were highly interrelated. Subtypes switched during disease progression in up to 31.6% of patients. Transcriptional subtyping had a modest prognostic impact in both unstratified cohorts, but strongly improved outcomes in patients with KRT81 positive / GATA6 negative tumors treated with palliative or adjuvant gemcitabine-based chemotherapy. RNAseq expression data confirmed the findings. CONCLUSIONS Transcriptional subtypes have differential responses on palliative and adjuvant gemcitabine- based chemotherapy, but they may change during disease progression. Both employed subtyping systems are equivalent and can be used to inform clinical therapy decisions. CLINICAL TRIAL REGISTRY The clinical trial registry identifier is NCT00440167 .

Year:

2024

Purpose: We evaluated additional mutations in RAS wild-type (WT) metastatic colorectal cancer (mCRC) as prognostic and predictive biomarkers for the efficacy of added panitumumab to a 5-fluorouracil plus folinic acid (FU/FA) maintenance as pre-specified analysis of the randomized PanaMa trial. Patients and Methods: Mutations (MUT) were identified using targeted next-generation sequencing (NGS; Illumina Cancer Hotspot Panel v2) and IHC. RAS/BRAF V600E /PIK3CA/AKT1/ALK1/ERBB2/PTEN MUT and HER2/neu overexpressions were negatively hyperselected and correlated with median progression-free survival (PFS) and overall survival (OS) since start of maintenance treatment, and objective response rates (ORR). Univariate/multivariate Cox regression estimated hazard ratios (HR) and 95% confidence intervals (CI). Results: 202 of 248 patients (81.5%) of the full analysis set (FAS) had available NGS data: hyperselection WT, 162 (80.2%); MUT, 40 (19.8%). From start of maintenance therapy, hyperselection WT tumors were associated with longer median PFS as compared with hyperselection MUT mCRC (7.5 vs. 5.4 months; HR, 0.75; 95% CI, 0.52–1.07; P = 0.11), OS (28.7 vs. 22.2 months; HR, 0.53; 95% CI, 0.36–0.77; P = 0.001), and higher ORR (35.8% vs. 25.0%, P = 0.26). The addition of panitumumab to maintenance was associated with significant benefit in hyperselection WT tumors for PFS (9.2 vs. 6.0 months; HR, 0.66; 95% CI, 0.47–0.93; P = 0.02) and numerically also for OS (36.9 vs. 24.9 months; HR, 0.91; 95% CI, 0.61–1.36; P = 0.50), but not in hyperselection MUT tumors. Hyperselection status interacted with maintenance treatment arms in terms of PFS ( P = 0.06) and OS ( P = 0.009). Conclusions: Extended molecular profiling beyond RAS may have the potential to improve the patient selection for anti-EGFR containing maintenance regimens.

Year:

2024

Purpose: We evaluated additional mutations in RAS wild-type (WT) metastatic colorectal cancer (mCRC) as prognostic and predictive biomarkers for the efficacy of added panitumumab to a 5-fluorouracil plus folinic acid (FU/FA) maintenance as pre-specified analysis of the randomized PanaMa trial. Patients and Methods: Mutations (MUT) were identified using targeted next-generation sequencing (NGS; Illumina Cancer Hotspot Panel v2) and IHC. RAS/BRAF V600E /PIK3CA/AKT1/ALK1/ERBB2/PTEN MUT and HER2/neu overexpressions were negatively hyperselected and correlated with median progression-free survival (PFS) and overall survival (OS) since start of maintenance treatment, and objective response rates (ORR). Univariate/multivariate Cox regression estimated hazard ratios (HR) and 95% confidence intervals (CI). Results: 202 of 248 patients (81.5%) of the full analysis set (FAS) had available NGS data: hyperselection WT, 162 (80.2%); MUT, 40 (19.8%). From start of maintenance therapy, hyperselection WT tumors were associated with longer median PFS as compared with hyperselection MUT mCRC (7.5 vs. 5.4 months; HR, 0.75; 95% CI, 0.52–1.07; P = 0.11), OS (28.7 vs. 22.2 months; HR, 0.53; 95% CI, 0.36–0.77; P = 0.001), and higher ORR (35.8% vs. 25.0%, P = 0.26). The addition of panitumumab to maintenance was associated with significant benefit in hyperselection WT tumors for PFS (9.2 vs. 6.0 months; HR, 0.66; 95% CI, 0.47–0.93; P = 0.02) and numerically also for OS (36.9 vs. 24.9 months; HR, 0.91; 95% CI, 0.61–1.36; P = 0.50), but not in hyperselection MUT tumors. Hyperselection status interacted with maintenance treatment arms in terms of PFS ( P = 0.06) and OS ( P = 0.009). Conclusions: Extended molecular profiling beyond RAS may have the potential to improve the patient selection for anti-EGFR containing maintenance regimens.

Year:

2024

Year:

2024

Year:

2023

Collaborators (14)

Ines Gockel

University Hospital Leipzig

GERMANY
View details

Michael East

Research Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Stefan Kasper

Professor of Medical Oncology

-

GERMANY
View details

Peter C. Thuss-Patience

University Hospital

GERMANY
View details

Sebastian Stintzing

Professor

Charité - Universitätsmedizin Berlin

GERMANY
View details

Jochen Gaedcke

University Medical Center

GERMANY
View details

Dominik P. Modest

-

GERMANY
View details

Steffen Ormanns

Medical University of Innsbruck

AUSTRIA
View details

Jen Jen Yeh

-

UNITED STATES
View details

Xianlu Laura Peng

University of North Carolina at Chapel Hill

UNITED STATES
View details

Beate Rau

Chair of Special Surgical Oncology

Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum

GERMANY
View details

Shawn Gomez

Peter Tong Department Chair and Professor

University of Wisconsin-Madison

UNITED STATES
View details

Lars Bullinger

Charité University Medicine

GERMANY
View details

Andreas Brandl

Attending Surgical Oncologist

University Hospital Heidelberg

GERMANY
View details